Prevalence and treatment of non-motor symptoms in Parkinson’s disease
Sullivan, KL, CL Ward, RA Hauser, and TA Zesiewicz. 2007. “Prevalence and Treatment of Non-Motor Symptoms in Parkinson’s Disease”. Parkinsonism Relat Disord.
Search
Search results
1934 results found
A randomized clinical trial of Coenzyme Q10 and GPI-1485 in early Parkinson's disease.
Investigators, The NINDS NET-PD, and RA Hauser. 2007. “A Randomized Clinical Trial of Coenzyme Q10 and GPI-1485 in Early Parkinson’s Disease.”. Neurology.
A Double-Blind placebo-controlled trial of zonisamide (Zonegran) in the treatment of essential tremor.
Zesiewicz, TA, CL Ward, RA Hauser, J Sanchez-Ramos, JF Staffetti, and K Sullivan. 2007. “A Double-Blind Placebo-Controlled Trial of Zonisamide (Zonegran) in the Treatment of Essential Tremor.”. Movement Disorders.
Leucine-rich repeat kinase 1: a paralog of LRRK2 and a candidate gene for Parkinson’s disease.
Taylor, JP, MM Hulihan, JM Kachergus, HL Melrose, SJ Lincoln, KM Hinkle, JT Stone, et al. 2007. “Leucine-Rich Repeat Kinase 1: a Paralog of LRRK2 and a Candidate Gene for Parkinson’s Disease.”. Neurogenetics.
Early treatment of Parkinson’s disease: how and when should therapy be initiated?
Hauser, RA. 2007. “Early Treatment of Parkinson’s Disease: How and When Should Therapy Be Initiated?”. Therapeutic Spotlight.
A pilot, double-blind, placebo-controlled trial of pregabalin (lyrica) in the treatment of essential tremor.
Zesiewicz, TA, CL Ward, RA Hauser, JL Salemi, S Siraj, MC Wilson, and KL Sullivan. 2007. “A Pilot, Double-Blind, Placebo-Controlled Trial of Pregabalin (lyrica) in the Treatment of Essential Tremor.”. Mov Disord.
Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease.
Group, Parkinson Study, and RA Hauser. 2007. “Mixed Lineage Kinase Inhibitor CEP-1347 Fails to Delay Disability in Early Parkinson Disease.”. Neurology.
End-of-dose wearing off in Parkinson disease: a 9-question survey assessment.
Stacy, M, RA Hauser, W Oertel, A Shapira, K Sethi, F Stocchi, and E Tolosa. 2006. “End-of-Dose Wearing off in Parkinson Disease: A 9-Question Survey Assessment.”. Clin Neuropharmacol.
Levetiracetam-Induced parkinsonism in a Huntington disease patient. Clin Neuropharmacol 2005;28:188-190.
Zesiewicz, TA, J Sanchez-Ramos, KL Sullivan, and RA Hauser. 2005. “Levetiracetam-Induced Parkinsonism in a Huntington Disease Patient. Clin Neuropharmacol 2005;28:188-190.”. Clin Neuropharmacol.
Levetiracetam for the treatment of generalized dystonia. Parkinsonism Relat Disord 2005;11:469-471.
Sullivan, KL, RA Hauser, ED Louis, G Chari, and TA Zesiewicz. 2005. “Levetiracetam for the Treatment of Generalized Dystonia. Parkinsonism Relat Disord 2005;11:469-471.”. Parkinsonism Relat Disord.